• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Obinutuzumab in Refractory Phospholipase A2 receptor-Associated Membranous Nephropathy With Severe CKD.

作者信息

Naik Sachin, Shukla Shubham, Av Niranjan, Kumar Vinod, Sekar Aravind, Nada Ritambhra, Rathi Manish, Kohli Harbir Singh, Ramachandran Raja

机构信息

Department of Nephrology, Postgraduate Institute of Medical Education and Research, Chandigarh, India.

Department of Dermatology, venereology and Leprosy, Postgraduate Institute of Medical Education and Research, Chandigarh, India.

出版信息

Kidney Int Rep. 2023 Jan 31;8(4):942-943. doi: 10.1016/j.ekir.2023.01.035. eCollection 2023 Apr.

DOI:10.1016/j.ekir.2023.01.035
PMID:37069971
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10105038/
Abstract
摘要

相似文献

1
Obinutuzumab in Refractory Phospholipase A2 receptor-Associated Membranous Nephropathy With Severe CKD.奥妥珠单抗治疗伴有严重慢性肾脏病的难治性磷脂酶A2受体相关膜性肾病
Kidney Int Rep. 2023 Jan 31;8(4):942-943. doi: 10.1016/j.ekir.2023.01.035. eCollection 2023 Apr.
2
Treatment resistant M-type phospholipase A2 receptor associated membranous nephropathy responds to obinutuzumab: a report of two cases.治疗抵抗型 M 型磷酸酶 A2 受体相关膜性肾病对奥滨尤妥珠单抗治疗有效：两例报告。
BMC Nephrol. 2022 Apr 7;23(1):134. doi: 10.1186/s12882-022-02761-3.
3
Successful Treatment of Patients With Refractory PLAR-Associated Membranous Nephropathy With Obinutuzumab: A Report of 3 Cases.奥滨尤妥珠单抗成功治疗难治性 PLAR 相关膜性肾病 3 例报告。
Am J Kidney Dis. 2020 Dec;76(6):883-888. doi: 10.1053/j.ajkd.2020.02.444. Epub 2020 Apr 18.
4
M-type phospholipase A2 receptor autoantibodies and renal function in patients with primary membranous nephropathy.原发性膜性肾病患者的M型磷脂酶A2受体自身抗体与肾功能
Clin J Am Soc Nephrol. 2014 Nov 7;9(11):1883-90. doi: 10.2215/CJN.03850414. Epub 2014 Sep 29.
5
Very early recurrence of anti-Phospholipase A2 receptor-positive membranous nephropathy after transplantation.移植后抗磷脂酶 A2 受体阳性膜性肾病的早期复发。
Am J Transplant. 2012 Jun;12(6):1637-42. doi: 10.1111/j.1600-6143.2011.03957.x. Epub 2012 Mar 5.
6
Clinical value of renal phospholipase A2 receptor deposit in the prognosis evaluation and treatment options of idiopathic membranous nephropathy: A retrospective cohort study.特发性膜性肾病预后评估和治疗选择中肾磷脂酶 A2 受体沉积的临床价值：一项回顾性队列研究。
Nephrology (Carlton). 2020 Mar;25(3):219-229. doi: 10.1111/nep.13691. Epub 2020 Jan 20.
7
Phospholipase A2 Receptor Antibody IgG4 Subclass Improves Sensitivity and Specificity in the Diagnosis of Idiopathic Membranous Nephropathy.磷脂酶 A2 受体抗体 IgG4 亚类提高特发性膜性肾病诊断的敏感性和特异性。
Kidney Blood Press Res. 2019;44(4):848-857. doi: 10.1159/000500456. Epub 2019 Jun 26.
8
Rituximab in Patients With Phospholipase A2 Receptor-Associated Membranous Nephropathy and Severe CKD.利妥昔单抗用于磷脂酶A2受体相关膜性肾病和重度慢性肾脏病患者
Kidney Int Rep. 2019 Dec 20;5(3):331-338. doi: 10.1016/j.ekir.2019.12.006. eCollection 2020 Mar.
9
Evaluation of efficacy of rituximab for membranous nephropathy: A systematic review and meta-analysis of 11 studies.评价利妥昔单抗治疗膜性肾病的疗效：11 项研究的系统评价和荟萃分析。
Nephrol Ther. 2022 Apr;18(2):104-112. doi: 10.1016/j.nephro.2021.10.002. Epub 2022 Jan 21.
10
Clinical significance of Mtype phospholipase A2 receptor and thrombospondin Type 1 domaincontaining 7A in primary membranous nephropathy.M型磷脂酶A2受体和含血小板反应蛋白1结构域7A在原发性膜性肾病中的临床意义
Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2020 Jun 28;45(6):693-700. doi: 10.11817/j.issn.1672-7347.2020.190109.

引用本文的文献

1
Efficacy and safety of obinutuzumab in primary membranous nephropathy: a real-world retrospective study.奥妥珠单抗治疗原发性膜性肾病的疗效与安全性：一项真实世界回顾性研究。
Front Immunol. 2025 Aug 21;16:1650054. doi: 10.3389/fimmu.2025.1650054. eCollection 2025.
2
Obinutuzumab is Effective as an Initial Treatment for PLA2R-Associated Primary Membranous Nephropathy: A Retrospective, Single-Center Trial.奥妥珠单抗作为磷脂酶A2受体相关原发性膜性肾病的初始治疗有效：一项回顾性单中心试验
Drug Des Devel Ther. 2025 Jul 11;19:5961-5972. doi: 10.2147/DDDT.S527661. eCollection 2025.
3
Obinutuzumab as a Promising Treatment for Membranous Nephropathy.奥妥珠单抗作为膜性肾病的一种有前景的治疗方法。
Indian J Nephrol. 2025 May-Jun;35(3):322-323. doi: 10.25259/IJN_391_2024. Epub 2024 Oct 10.
4
Obinutuzumab is effective for the treatment of rituximab-refractory PLA2R-associated membranous nephropathy.奥妥珠单抗对利妥昔单抗难治性磷脂酶A2受体相关膜性肾病的治疗有效。
Clin Kidney J. 2025 May 1;18(5):sfaf026. doi: 10.1093/ckj/sfaf026. eCollection 2025 May.
5
Newer B-cell and plasma-cell targeted treatments for rituximab-resistant patients with membranous nephropathy.针对利妥昔单抗耐药的膜性肾病患者的新型B细胞和浆细胞靶向治疗方法。
Clin Kidney J. 2025 Mar 21;18(5):sfaf088. doi: 10.1093/ckj/sfaf088. eCollection 2025 May.
6
Obinutuzumab for treatment of membranous nephropathy in patients positive and negative for the phospholipase A receptor antibody: case reports.奥妥珠单抗治疗磷脂酶A受体抗体阳性和阴性患者的膜性肾病：病例报告
Front Immunol. 2025 Apr 15;16:1561638. doi: 10.3389/fimmu.2025.1561638. eCollection 2025.
7
Obinutuzumab and Ofatumumab are More Effective Than Rituximab in the Treatment of Membranous Nephropathy Patients With Anti-Rituximab Antibodies.奥妥珠单抗和奥法木单抗在治疗伴有抗利妥昔单抗抗体的膜性肾病患者方面比利妥昔单抗更有效。
Kidney Int Rep. 2024 Dec 17;10(3):753-761. doi: 10.1016/j.ekir.2024.12.012. eCollection 2025 Mar.
8
Obinutuzumab in membranous nephropathy: a potential game-changer in treatment.奥妥珠单抗治疗膜性肾病：治疗领域的潜在变革者
Drugs Context. 2025 Feb 21;14. doi: 10.7573/dic.2024-9-1. eCollection 2025.
9
Obinutuzumab in Difficult to Treat Phospholipase A2 Receptor Positive Membranous Nephropathy: Our Experience at a Tertiary Care Center in North India.奥妥珠单抗治疗难治性磷脂酶A2受体阳性膜性肾病：我们在印度北部一家三级医疗中心的经验。
Indian J Nephrol. 2025 Jan-Feb;35(1):91-96. doi: 10.25259/ijn_498_23. Epub 2024 Jul 8.
10
Post-transplant glomerular diseases: update on pathophysiology, risk factors and management strategies.移植后肾小球疾病：病理生理学、危险因素及管理策略的最新进展
Clin Kidney J. 2024 Oct 24;17(12):sfae320. doi: 10.1093/ckj/sfae320. eCollection 2024 Dec.

本文引用的文献

1
Immunosuppressive Therapy in Primary Membranous Nephropathy with Compromised Renal Function.肾功能受损的原发性膜性肾病的免疫抑制治疗
Nephron. 2022;146(2):138-145. doi: 10.1159/000518609. Epub 2021 Nov 3.
2
Rituximab in Patients With Phospholipase A2 Receptor-Associated Membranous Nephropathy and Severe CKD.利妥昔单抗用于磷脂酶A2受体相关膜性肾病和重度慢性肾脏病患者
Kidney Int Rep. 2019 Dec 20;5(3):331-338. doi: 10.1016/j.ekir.2019.12.006. eCollection 2020 Mar.
3
Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions.奥滨尤妥珠单抗联合苯丁酸氮芥治疗伴有合并症的 CLL 患者。
N Engl J Med. 2014 Mar 20;370(12):1101-10. doi: 10.1056/NEJMoa1313984. Epub 2014 Jan 8.